SciELO - Scientific Electronic Library Online

 
vol.11 número6Factores que influyen en el uso de los protocolos clínicos, según la opinión de los fisioterapeutas de los centros de salud de la región de MurciaLa picadura del pez araña índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Medifam

versión impresa ISSN 1131-5768

Resumen

BENITO RUIZ, P.  y  PROS SIMON, A.. Why an early treatment in rheumatoid arthritis?. Medifam [online]. 2001, vol.11, n.6, pp.53-61. ISSN 1131-5768.

Rheumatoid arthritis is an autoimmune disease characterized by chronic inflammation of diarthrodial joints, which may also cause involment of other organs. Today, most authors agree that nearly 80% of the patients will present with some degreee of disability after 10 years evolution. Prognosis of rheumatoid arthritis is uncertain, and lesions, that are produced in the first years of the disease, may progress despite clinical improvement, since pathogenesis of these lesions may differ from simple acute joint inflammation. Early diagnosis is therefore essential in order to start treatment before structural joint damage develops, since there is evidence that patients treated during the first year from the beginning of symptoms present better functional capacity outcome than those treated later.  Classic treatment for this disease had been based, until recently, on the traditional therapeutic pyramid which consisted in sequential introduction of drugs. Poor results of this strategy and awareness of the bad prognosis of the disease has demanded a reevaluation of its therapeutic approach. In this sense, introduction of remission induction agents early in the course of the disease seems appropiate, with the aim of reducing morbidity and functional disability.

Palabras clave : Rheumatoid arthritis; Treatment.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons